A comparison of health utility measures for the evaluation of multiple sclerosis treatments

被引:165
作者
Fisk, JD
Brown, MG
Sketris, IS
Metz, LM
Murray, TJ
Stadnyk, KJ
机构
[1] Dalhousie Univ, Dept Med, Halifax, NS, Canada
[2] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada
[3] Capital Dist Hlth Author, Halifax, NS, Canada
[4] Dalhousie Univ, Dept Epidemiol & Community Hlth, Halifax, NS, Canada
[5] Dalhousie Univ, Coll Pharm, Halifax, NS B3H 3J5, Canada
[6] Univ Calgary, Dept Clin Neurol Sci, Calgary, AB, Canada
关键词
D O I
10.1136/jnnp.2003.017897
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To evaluate the practical application and psychometric properties of three health utility measures in a sample of MS patients with a broad range of neurological disability as measured by the Extended Disability Status Scale (EDSS). Methods: Patients randomly selected from two MS clinic registries were assessed using standard clinical methods and completed three generic measures of health utility (EQ-5D, HUI Mark III, SF-6D). The proportion of missing data, test/retest reliability, and construct validity of each health utility measure were examined. Results: The assessments were completed by 187 patients. Less than 10% of data were missing for the subscales of the SF-6D (<3.2%), HUI Mark III (<1.6%), and EQ-5D (less than or equal to7.5%). Severely disabled patients were more likely to omit physical function questions for the SF-6D (20%), and EQ-5D (43%). Retest reliability for the SF-6D (ICC = 0.83), EQ-5D (ICC = 0.81), and HUI Mark III (ICC = 0.87) were adequate for population surveys. Correlations between assessment of clinical function and each health utility measure were strongest for the HUI Mark III (HUI Mark III EDSS rho = -0.77, HUI Mark III ambulation index rho = -0.76, HUI Mark III timed 25 foot walk rho = -0.73, HUI Mark III nine hole peg test rho = -0.65). Conclusions: The health utility measures were generally feasible and reliable but the HUI Mark III demonstrated highest concordance with the EDSS across the full range of neurological disability. Of the three measures studied, the HUI Mark III may be the most appropriate for cost effectiveness evaluations of MS therapies.
引用
收藏
页码:58 / 63
页数:6
相关论文
共 40 条
[1]   Quality of life during the first 6 months of interferon-β treatment in patients with MS [J].
Arnoldus, JHA ;
Killestein, J ;
Pfennings, LEMA ;
Jelles, B ;
Uitdehaag, BMJ ;
Polman, CH .
MULTIPLE SCLEROSIS, 2000, 6 (05) :338-342
[2]   Deriving a preference-based single index from the UK SF-36 Health Survey [J].
Brazier, J ;
Usherwood, T ;
Harper, R ;
Thomas, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1115-1128
[3]   Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression - First estimation [J].
Brown, MG ;
Murray, TJ ;
Sketris, IS ;
Fisk, JD ;
LeBlanc, JC ;
Schwartz, CE ;
Skedgel, C .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2000, 16 (03) :751-767
[4]   Measuring health outcomes [J].
Cairns, J .
BRITISH MEDICAL JOURNAL, 1996, 313 (7048) :6-6
[5]  
Dolan P., 1995, SOCIAL TARIFF EUROQO
[6]  
Drummond M., 2015, Methods for the Economic Evaluation of Health Care Programmes, DOI DOI 10.1016/S0749-3797(97)00069-X
[7]  
Feeny D., 1996, QUALITY LIFE PHARMAC, P239
[8]   Developing a disease-specific quality of life measure for people with multiple sclerosis [J].
Ford, HL ;
Gerry, E ;
Tennant, A ;
Whalley, D ;
Haigh, R ;
Johnson, MH .
CLINICAL REHABILITATION, 2001, 15 (03) :247-258
[9]  
Francis G, 2001, NEUROLOGY, V56, P1628
[10]   Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis [J].
Freeman, J ;
Hobart, JC ;
Langdon, DW ;
Thompson, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (02) :150-156